Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Completes First Closing of Private Placement

NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a...
November 14, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Third Quarter 2019 Results

TORONTO and CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
November 13, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Undertaking $6.5M Private Placement

TORONTO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN; OTCQB:ARFXF), a biotechnology company focused on the discovery and development of...
November 07, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease

TORONTO and CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
October 23, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43

TORONTO and CAMBRIDGE, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
October 17, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau

TORONTO and CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
October 08, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy

TORONTO and CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
September 16, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit

TORONTO and CAMBRIDGE, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
September 03, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Present at H.C. Wainwright Investor Conference

TORONTO and CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
August 27, 2019 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer’s Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board

TORONTO and CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...